Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RPT904 · 1 trial · 1 indication
Proportion of participants who consumed a single dose of ≥600 mg (ie, a cumulative dose of ≥1044 mg) of peanut or cashew protein, or a single dose of ≥1000 mg (ie, a cumulative dose of ≥2044 mg) of milk, egg, or walnut protein without dose-limiting symptoms at Part 1 DBPCFC
| Arm | Type | Description |
|---|---|---|
| RPT904 (Q8W) | EXPERIMENTAL | RPT904 every 8 weeks. The dose levels of RPT904 (150 mg, 300 mg, and 600 mg) within the Q8W cohort will be assigned based on participant weight and baseline total IgE level. RPT904 subcutaneous injection every 8 weeks with a loading dose at Week 2 (Part 1: 24 weeks; Part 2: 24 weeks); matching placebo at intervening visits to maintain blinding. |
| RPT904 (Q12W) | EXPERIMENTAL | RPT904 every 12 weeks. The dose levels of RPT904 (150 mg, 300 mg, and 600 mg) will be assigned based on participant weight and baseline total IgE level. RPT904 subcutaneous injection every 12 weeks with a loading dose at Week 2 (Part 1: 24 weeks; Part 2: 24 weeks); matching placebo at intervening visits to maintain blinding. |
| Placebo | PLACEBO_COMPARATOR | Placebo subcutaneous injection on schedules matching both the Q8W and Q12W arms in Part 1 (24 weeks); RPT904 every 8 or 12 weeks with a loading dose at Week 26 on schedules matching both the Q8W and Q12W arms Part 2 (24 weeks), with matching placebo at intervening visits to maintain blinding. |
| Name | Type | Description |
|---|---|---|
| RPT904 | DRUG | Subcutaneous injection once every 8 weeks |
| Placebo | OTHER | Subcutaneous injection at the intervening dosing visits |
Key Inclusion Criteria: * Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable. * Male or female, 12 to less than 56 years of age at screening. * Allergic to at least 1 of the following foods: peanut, milk, egg, cashew, or wal...
RPT904 is an investigational small molecule being developed for the treatment of IgE-mediated food allergy. It is currently in Phase 2 clinical development and is being studied as a monotherapy in participants with this condition.
RPT904 is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its potential to treat IgE-mediated food allergy, a condition where the immune system overreacts to certain foods.
RPT904 is being developed by RAPT Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RAPT.
RPT904 is currently in Phase 2 clinical development. It is being evaluated in a Phase 2b study as a monotherapy for IgE-mediated food allergy, and the trial is actively recruiting participants.
RPT904 is being studied in a Phase 2b clinical trial with the identifier NCT07220811. This randomized, double-blind, placebo-controlled trial is recruiting 100 participants aged 12 years and older with IgE-mediated food allergy across the United States, Australia, and Canada.